What it sells
Extrapolative AI to unlock First-in-Class drugs
Business model breakdown
Workflow: what inputs become what output?
Extrapolative frontier models for targets with no training data to find chemical starting points for oral small molecules.
Economics: what it saves and how it charges
Biotech: drug programs and partnerships; $200B treatable disease without a pill cited.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.